Executive director

Earl J. Reisdorff, M.D., to Step Down from the American Board of Emergency Medicine

Retrieved on: 
Wednesday, January 10, 2024
Multimedia, ABEM, Retirement, Emergency medicine, Learning, Partnership, Certification, Executive director, M.B.A, Executive

EAST LANSING, Mich., Jan. 10, 2024 /PRNewswire/ -- After 14 years, Earl J. Reisdorff, M.D., will be stepping down as the Executive Director of the American Board of Emergency Medicine (ABEM).

Key Points: 
  • EAST LANSING, Mich., Jan. 10, 2024 /PRNewswire/ -- After 14 years, Earl J. Reisdorff, M.D., will be stepping down as the Executive Director of the American Board of Emergency Medicine (ABEM).
  • Dr. Reisdorff joined ABEM in 2010 as its third Executive Director in 31 years.
  • He actively sought innovations that would make certification more relevant and convenient for emergency physicians and implemented a system of physician-focused engagement and service.
  • The Executive Director, Professional and Clinical Affairs will serve in a recently created dyad model with the Executive Director for Administrative Affairs.

Arkadios Capital Marks Growth and Success in 2023, Eyes Continued Expansion in 2024

Retrieved on: 
Wednesday, January 10, 2024
RIA, IBD, ACG, Atlanta Business Chronicle, ELITE, Executive director, Business consultant, Strategic management, Growth, Financial adviser

ATLANTA, Jan. 10, 2024 /PRNewswire/ -- Arkadios Capital, a leading hybrid broker-dealer, marks another year of remarkable growth, adding 15 advisory groups and nearly $3 billion in new assets to their platform.

Key Points: 
  • ATLANTA, Jan. 10, 2024 /PRNewswire/ -- Arkadios Capital, a leading hybrid broker-dealer, marks another year of remarkable growth, adding 15 advisory groups and nearly $3 billion in new assets to their platform.
  • "As we enter 2024, Arkadios remains dedicated to providing larger teams and advisors with an elite platform to power their business and better serve clients," said Founder and CEO David Millican.
  • For the second consecutive year, Arkadios Capital earned a coveted spot on the prestigious Association of Corporate Growth (ACG) Georgia Chapter Fast 40 list, a testament to the company's sustained growth and success.
  • Arkadios Capital anticipates building on this momentum in 2024, fostering continued growth, innovation and unparalleled support for its advisors.

Dr. Rachel Brem joins Breathe BioMedical as Executive Director and Chief Medical Officer

Retrieved on: 
Tuesday, January 9, 2024
Mortality, Artificial intelligence, Woman, Sinai Hospital, Johns Hopkins Hospital, Regulation, Legislation, Internal medicine, Newsweek, BBM, Health equity, George Washington University, Breast cancer, Clinical, Executive, Breast imaging, Radiology, Regular-Irregular, Executive director, Organization, Education, Diagnosis, Trial of the century, Medical imaging

MONCTON, NB, Jan. 9, 2024 /PRNewswire/ - Breathe BioMedical (BBM) is pleased to announce the appointment of Dr. Rachel Brem to the company's Board of Directors in her newly appointed role of Executive Director and Chief Medical Officer.

Key Points: 
  • MONCTON, NB, Jan. 9, 2024 /PRNewswire/ - Breathe BioMedical (BBM) is pleased to announce the appointment of Dr. Rachel Brem to the company's Board of Directors in her newly appointed role of Executive Director and Chief Medical Officer.
  • Dr. Brem is a world-renowned expert in breast cancer and the Director of the Breast Imaging and Interventional Center at the George Washington University.
  • Dr. Brem is the Chief Medical Officer of the Brem Foundation, a 501(c) 3 which began nearly 20 years ago, inspired by her mission and life story that is dedicated to the early detection of breast cancer.
  • "We are excited to have Dr. Brem's leadership at the Executive Director level to lead our Clinical and Regulatory strategy as our Chief Medical Officer."

Denyce Graves Foundation Appoints Terry Eberhardt as Executive Director, Fortifying Commitment to Equity in Classical Vocal Arts

Retrieved on: 
Tuesday, January 9, 2024
Art, Young British Artists, DGF, Executive director, Education, Growth

BALTIMORE, Jan. 9, 2024 /PRNewswire/ -- The Denyce Graves Foundation (DGF) is delighted to announce the appointment of Terry Eberhardt as its new Executive Director, marking a significant stride towards advancing equity and inclusion in American classical vocal arts.

Key Points: 
  • BALTIMORE, Jan. 9, 2024 /PRNewswire/ -- The Denyce Graves Foundation (DGF) is delighted to announce the appointment of Terry Eberhardt as its new Executive Director, marking a significant stride towards advancing equity and inclusion in American classical vocal arts.
  • Boasting an illustrious career in arts management, education, and advocacy, Eberhardt brings a wealth of experience to his new role.
  • As the Executive Director, he will play a crucial role in shaping the strategic direction of the Foundation, fostering collaborative partnerships, and driving the organization's vision to reshape the landscape of classical vocal arts.
  • Denyce Graves-Montgomery, the Emmy® and Grammy® award-winning mezzo-soprano, and Founder and Artistic Director of DGF, warmly welcomes Eberhardt to the team, stating, "We are thrilled to welcome Terry Eberhardt as our Executive Director.

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Retrieved on: 
Thursday, January 4, 2024
Cosmetics, Retail, Pharmaceutical, Health, Small Business Administration, University School, Public policy, Corporate Affairs, Medicine, Biotechnology Innovation Organization, Booz Allen Hamilton, Corporate communication, Georgetown University, Narek, Graduate diploma, FTI Consulting, Intercept Pharmaceuticals, Treasury, Small business, University, Public sector, Executive director, Corporate finance, Carey Business School, Management

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications.
  • In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program.
  • “Nareg’s unique experience will enable him to drive a successful investor relations strategy that communicates Evolus’ strategic goals to our stakeholders.”
    Prior to joining Evolus, Nareg was the Executive Director, Head of Global Investor Relations, Corporate Affairs for Intercept Pharmaceuticals.
  • Nareg brings extensive experience in capital markets, investor relations, corporate communications, and public policy to Evolus from firms including FTI Consulting, Biotechnology Innovation Organization and Booz Allen Hamilton.

Wesley Griffin Appointed as The Executive Director of The Collective Gain Foundation Wednesday, January 3rd, 2024

Retrieved on: 
Wednesday, January 3, 2024
Entrepreneurship, Executive, Christian Lane, Growth, Executive director, Organization, Management

AUSTIN, Texas, Jan. 3, 2024 /PRNewswire-PRWeb/ -- The Collective Gain Foundation is proud to announce the appointment of Wesley Griffin as Executive Director, effective January 3rd, 2024. With a proven track record of leadership and a commitment to social impact, Wesley brings a wealth of experience to this esteemed role.

Key Points: 
  • The Collective Gain Foundation is proud to announce the appointment of Wesley Griffin as Executive Director, effective January 3rd, 2024.
  • AUSTIN, Texas, Jan. 3, 2024 /PRNewswire-PRWeb/ -- The Collective Gain Foundation is proud to announce the appointment of Wesley Griffin as Executive Director, effective January 3rd, 2024.
  • "We are thrilled to welcome Wesley as the Executive Director of the Collective Gain Foundation," said Christian Lane, Co-Founder and Chairman of the Board.
  • "I am honored to take on the role of Executive Director at the Collective Gain Foundation," said Wesley.

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Retrieved on: 
Thursday, November 30, 2023
Dermatology, Probability, FDA, Nevoid basal-cell carcinoma syndrome, Disease, Sol–gel process, Breakthrough, BCC, Patient, Carcinoma, Executive director, NESS, KOL, Pharmaceutical industry

Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.

Key Points: 
  • Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.
  • "We are pleased to initiate patient screening in this Phase 3 trial that has been long awaited by the Gorlin syndrome patient community,” said Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel.
  • Sol-Gel will conduct the Phase 3 study to investigate SGT-610 in approximately 140 subjects at approximately 40 experienced clinical centers in North America, United Kingdom and Europe.
  • The event will highlight the patient’s experience through the eyes of a Gorlin syndrome patient as well as discuss the therapeutic potential of SGT-610 to prevent new BCCs in Gorlin syndrome patients and Sol-Gel’s Phase 3 trial.

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

Retrieved on: 
Tuesday, November 28, 2023
Dermatology, FDA, Nevoid basal-cell carcinoma syndrome, Disease, Sol–gel process, Doctor of Philosophy, Therapy, Genetic disorder, HHI, Growth, BCC, Patient, Carcinoma, Executive director, NESS, KOL, Pharmaceutical industry

The event will feature Julie Breneiser (Executive Director, Gorlin Syndrome Alliance) and Ervin Epstein Jr., MD (Co-Founder of PellePharm Inc.), who will discuss the significant disease burden of Gorlin syndrome patients and lack of effective therapies.

Key Points: 
  • The event will feature Julie Breneiser (Executive Director, Gorlin Syndrome Alliance) and Ervin Epstein Jr., MD (Co-Founder of PellePharm Inc.), who will discuss the significant disease burden of Gorlin syndrome patients and lack of effective therapies.
  • Gorlin syndrome is a rare genetic disorder associated with growth of multiple basal cell carcinomas.
  • SGT-610 has been granted Orphan Drug Designation as well as Breakthrough Designation by the FDA.
  • Alon Seri-Levy, PhD (Co-Founder and Chief Executive Officer, Sol-Gel Therapeutics) will provide an overview of the upcoming SGT-610 Phase 3 study, including strategies intended to optimize success of the study, and insights on market potential.

Management Board meeting: 5 October 2023, European Medicines Agency, Amsterdam, the Netherlands, 5 October 2023

Retrieved on: 
Monday, December 18, 2023
Executive director, Agency

Management Board meeting: 5 October 2023

Key Points: 

Management Board meeting: 5 October 2023
EventCorporateGovernance
Date
Location
The Management Board is an integral governance body of the Agency. It has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director and the monitoring of the Agency's performance.

Management Board meeting: 13-14 December 2023, European Medicines Agency, Amsterdam, the Netherlands, from 13 December 2023 to 14 December 2023

Retrieved on: 
Monday, December 18, 2023
Executive director, Agency

Management Board meeting: 13-14 December 2023

Key Points: 

Management Board meeting: 13-14 December 2023
The Management Board is an integral governance body of the Agency. It has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director and the monitoring of the Agency's performance.
EventCorporateGovernance